Apellis Pharmaceuticals (APLS) PT Raised to $85 at Needham & Company After Previewing Phase 3 DERBY/OAKS Readout
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $85.00 (from $65.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
